Business
ZYUS Life Sciences Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent covering Trichomylin® Formulation and Announces Unit Offering
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES...
About this update from Zyus Life Sciences Corporation
[{"type":"text","content":"ZYUS Life Sciences Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent covering Trichomylin® Formulation and Announces Unit Offering\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n \n\n\n\n\n\n NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES\n \n\n\n\n\n\n ZYUS Life Sciences Corporation (the “\n \n Company\n \n ” and/or “\n \n ZYUS\n \n ”) (TSX-V: ZYUS), a clinical stage life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates, today announced that the European Patent Office has granted and the opposition period has expired respecting patent No. EP 3962473 entitled “Formulation For Pain Management”. This patent relates to ZYUS’ cannabinoid-based lead drug candidate, Trichomylin\n \n ®\n \n softgel capsules. The EU patent marks the 9\n \n th\n \n issuance of a patent in this patent family, joining other jurisdictions such as the United States, Canada, Australia, Israel, India, Korea, South Africa and Hong Kong. The EU patent has been validated in 22 European countries and carries a term effective until May 1, 2040.\n \n\n “The grant of this EU patent represents another milestone intended to drive shareholder value through expanded global protection of our novel fixed-dose formulation, Trichomylin\n \n ®\n \n softgel capsules,” said Brent Zettl, President and CEO of ZYUS. “We continue to believe in our highly differentiated approach to pain management and look forward to further advancing this non-opioid based pharmaceutical solution to ultimately address areas of significant unmet medical need.”\n \n\n Conservative estimates suggest that chronic pain affects over 1.5 billion people globally, or 20% of the world’s population (Goldberg DS, McGee SJ. “Pain as a global public heath priority” BMC Public Health 2011;11:770-774). With a view to providing a solution to this unmet need, ZYUS is currently advancing the development of Trichomylin\n \n ®\n \n softgel capsules in a Phase 2a, single-arm proof of concept study to investigate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules in humans with advanced cancer and...